Company Overview
Inotiv, Inc. operates within the healthcare sector, specifically serving the diagnostics and research industry by providing nonclinical and analytical drug discovery and development services to pharmaceutical and medical device companies across the United States, the Netherlands, and international markets. The enterprise functions through two primary segments, Discovery and Safety Assessment (DSA) and Research Model, delivering essential support for the early stages of drug development and safety testing. The company maintains a market capitalization of $9.29M and employs a workforce of 1945 individuals to generate annual revenue of $514.03M. While the revenue figure of $514.03M indicates a significant operational scale in terms of transaction volume, the market cap of $9.29M suggests a valuation that does not fully align with the current revenue generation, reflecting the market's assessment of future profitability or risk rather than current cash flow.
Financial Health
The company reported revenue of $514.03M over the trailing twelve months, yet this revenue figure is offset by a net income of -$69,373,000, revealing a substantial gap that highlights a highly leveraged cost structure where expenses significantly exceed gross profits. Despite the negative net income, the company posted an EBITDA of $17.68M, which provides a view of operating cash generation before financing costs and depreciation, though this figure contrasts sharply with the reported loss. The firm generated free cash flow of -$3,620,125, indicating a current burn rate that limits financial flexibility and suggests reliance on external capital or existing cash reserves to fund operations. Profitability is further constrained by a gross margin of 23.5%, an operating margin of -13.4%, and a profit margin of -13.5%, all of which indicate that the company is currently unable to convert a significant portion of its revenue into net profit due to high operating expenses relative to sales. The balance sheet shows a cash position of $12.73M against total debt of $475.97M, resulting in a debt-to-equity ratio of 436.57, which characterizes the balance sheet as extremely leveraged rather than conservative. This heavy debt load is compounded by a current ratio of 0.30, indicating that current assets are insufficient to cover current liabilities, thereby signaling potential short-term liquidity challenges. Additionally, the return on equity stands at -49.8% and the return on assets is -3.1%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the business.
Valuation Assessment
Valuation metrics for Inotiv, Inc. present a mixed picture, with a trailing P/E ratio of N/A and a forward P/E of -5.40, implying that the market anticipates earnings may remain negative in the near future or that current earnings do not support a traditional multiple. The price-to-book ratio is recorded at 0.09, suggesting the stock trades at a fraction of its book value, which often indicates a depressed market price relative to the company's tangible assets. Alternative valuation measures such as the price-to-sales ratio of 0.02 and an EV/EBITDA of 26.73 provide further context, showing the market values the company at less than 2% of its sales while assigning a high multiple to its earnings before interest, taxes, depreciation, and amortization. The stock's price volatility is evident in its 52-week range, which spans from a low of $0.25 to a high of $3.32, meaning the current trading position is situated at a specific point within this wide band relative to the historical extremes. The beta value of 4.22 indicates that the stock is highly volatile and is expected to fluctuate with significantly greater intensity than the broader market, exposing investors to substantial price swings relative to standard market movements.
Growth & Income
Revenue growth year-over-year stands at 0.8%, while earnings growth is listed as N/A, suggesting that revenue expansion is currently flat and that earnings have not yet turned positive to support a measurable growth rate. Because the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, implying that any available cash flow is retained within the business to cover debt obligations or fund operations rather than being reinvested for growth via dividends. This reinvestment strategy is necessitated by the negative free cash flow and the lack of distributable earnings, forcing the company to rely on equity issuance or debt refinancing to sustain operations. The overall growth and income profile is characterized by minimal revenue expansion and a complete absence of dividend income, reflecting a phase of financial restructuring where capital preservation takes precedence over shareholder distributions or organic earnings growth.